# US 12,215,135 B2 · PDL2 compounds > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 12,215,135 B2 - Document ID: US12215135B2 - Status: Granted - Kind: B2 - Application number: 17/819,280 - Filed: 2022-08-11 - Published: 2023-07-20 - Granted: 2025-02-04 - Earliest claimed: 2016-10-27 - Assignees: IO Biotech ApS - Applicants: Io Biotech Aps - Inventors: Mads Hald Andersen - Web page: https://patentgrep.com/patent/US12215135B2 ## CPC - C07K 14/70532: {B7 molecules, e.g. CD80, CD86} - A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants - A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells - A61K 40/421: {Immunoglobulin superfamily} - A61P 35/00: Antineoplastic agents - A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) - A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca - C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00) - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS ## Abstract The present invention relates to a peptide compound of PDL2 selected from a peptide fragment, a functional homologue, and a functional analogue, as well as to a nucleic acid, such as DNA or RNA, encoding the peptide compound, a vector, such as a virus vector, and a host cell, such as mammalian cell, comprising the vector. The peptide compound, nucleic acid, vector and host cell of the present invention are in particular, useful for the treatment or prevention of a cancer characterized by expression of PDL2. ## Claims ### Claim 1 A vaccine composition comprising a peptide, or a pharmaceutically acceptable salt thereof, wherein the peptide is an immunogenic peptide fragment of a human programmed death ligand 2 (PDL2) protein of SEQ ID NO: 1, and consists of a consecutive sequence of up to 60 amino acids of SEQ ID NO: 1, comprises an amino acid sequence selected from SEQ ID NOs: 2, 4, and 11, and does not comprise amino acids 1-3 of SEQ ID NO: 1; and an adjuvant. ### Claim 2 (depends on 1) The vaccine composition of claim 1, further comprising a pharmaceutically acceptable excipient. ### Claim 3 (depends on 2) The vaccine composition of claim 2, wherein the pharmaceutically acceptable excipient is a preservative. ### Claim 4 (depends on 1) The vaccine composition of claim 1, wherein the adjuvant is selected from the group consisting of a bacterial DNA based adjuvant, an oil/surfactant based adjuvant, a viral dsRNA based adjuvant, and an imidazoquinoline. ### Claim 5 (depends on 4) The vaccine composition of claim 4, wherein the oil/surfactant based adjuvant is a water-in-oil (W/O) emulsion composed of a mineral oil and a surfactant from the mannide monooleate family. ### Claim 6 (depends on 1) The vaccine composition of claim 1, wherein the immunogenic peptide fragment consists of a consecutive sequence from 10 to 17 amino acids, 20 to 30 amino acids, 30 to 40 amino acids, or 40 to 50 amino acids of SEQ ID NO: 1. ### Claim 7 (depends on 1) The vaccine composition of claim 1, wherein the consecutive sequence comprises SEQ ID NO: 11. ### Claim 8 (depends on 1) The vaccine composition of claim 1, wherein the consecutive sequence of SEQ ID NO: 1 comprises SEQ ID NO: 4. ### Claim 9 (depends on 1) The vaccine composition of claim 1, wherein the immunogenic peptide fragment is 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acids in length. ### Claim 10 (depends on 1) The vaccine composition of claim 1, wherein the immunogenic peptide fragment is an isolated peptide fragment. ### Claim 11 A vaccine composition comprising a nucleic acid encoding an immunogenic peptide fragment of a human programmed death ligand 2 (PDL2) protein of SEQ ID NO: 1; and a pharmaceutically acceptable additive, wherein the immunogenic peptide fragment consists of a consecutive sequence of up to 60 amino acids of SEQ ID NO: 1, comprises an amino acid sequence selected from SEQ ID NOs: 2, 4, and 11, and does not comprise amino acids 1-3 of SEQ ID NO: 1. ### Claim 12 (depends on 11) The vaccine composition of claim 11, wherein the nucleic acid is comprised within a vector. ### Claim 13 (depends on 11) The vaccine composition of claim 11, wherein the nucleic acid is DNA. ### Claim 14 (depends on 11) The vaccine composition of claim 11, wherein the nucleic acid is RNA. ### Claim 15 A nucleic acid encoding an immunogenic peptide fragment of a human programmed death ligand 2 (PDL2) protein of SEQ ID NO: 1, wherein the immunogenic peptide fragment consists of a consecutive sequence of up to 60 amino acids of SEQ ID NO: 1, comprises an amino acid sequence selected from SEQ ID NOs: 2, 4, and 11, and does not comprise amino acids 1-3 of SEQ ID NO: 1. ### Claim 16 (depends on 15) The nucleic acid of claim 15, wherein the nucleic acid is DNA. ### Claim 17 (depends on 15) The nucleic acid of claim 15, wherein the nucleic acid is RNA. ### Claim 18 (depends on 15) A vector comprising the nucleic acid of claim 15.